TELA Bio, Inc. (TELA)
NASDAQ: TELA · Real-Time Price · USD
1.580
0.00 (0.00%)
Sep 16, 2025, 4:00 PM EDT - Market closed
TELA Bio Revenue
TELA Bio had revenue of $20.20M in the quarter ending June 30, 2025, with 25.52% growth. This brings the company's revenue in the last twelve months to $75.32M, up 16.34% year-over-year. In the year 2024, TELA Bio had annual revenue of $69.30M with 18.56% growth.
Revenue (ttm)
$75.32M
Revenue Growth
+16.34%
P/S Ratio
0.82
Revenue / Employee
$360,397
Employees
209
Market Cap
62.59M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 69.30M | 10.85M | 18.56% |
Dec 31, 2023 | 58.45M | 17.04M | 41.13% |
Dec 31, 2022 | 41.42M | 11.96M | 40.58% |
Dec 31, 2021 | 29.46M | 11.25M | 61.77% |
Dec 31, 2020 | 18.21M | 2.77M | 17.91% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TELA News
- 5 weeks ago - TELA Bio, Inc. (TELA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - TELA Bio Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 2 months ago - TELA Bio to Announce Second Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair - GlobeNewsWire
- 3 months ago - TELA Bio Appoints Jeffrey Blizard as President - GlobeNewsWire